Asthma & Lung

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT)

Primary disease category: 

Your child is invited to participate because your child has a peanut allergy.  The study will last up to 72 weeks where you will take daily study drug, monthly study injections, complete study questionnaires/diaries, food challenge, skin prick tests, breathing tests, and have your blood drawn.

For Dupilumab there are common risks such as: conjunctivitis (pink eye), injection site reaction (swelling, redness, etc.), your child may experience a local or generalized allergic reaction (also known as a hypersensitivity reaction).

Primary disease category: 

This reseach is being done to try and find a way to help people with Asthma lose weight.

Primary disease category: 
Secondary disease category(ies): 

This reseach is being done to evaluate the effectiveness of using Roflumilast as an alternative treatement of poorly controlled Asthma in obese patients.

Primary disease category: 
Secondary disease category(ies): 

This study is being done to measure the symptoms which might limit the use of certain types of drugs and asses if a subject would be fit for future clinical trials.

Primary disease category: 
Secondary disease category(ies): 

A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.

Primary disease category: 

We want to find out if parents of young children will complete surveys sent to them by a text message to their smart phone or by email about their child’s breathing problems.

A one question survey will be sent every day for 4 months. Additional surveys will be sent if the child is developing a respiratory track illness to ask about symptoms.

Primary disease category: 

This research is being done to see if a medicine used to treat high blood pressure, Losartan, can slow the damage to the lungs in people who have COPD with emphysema. Currently, there are some medications for COPD to reduce symptoms and prevent exacerbations. However, there are no treatments to slow or stop the progression of the disease.

Primary disease category: 

The Oral Bacterial Extract (ORBEX) Study is a three year study to see whether the wheezing and lower respiratory tract illnesses that lead to asthma can be prevented. The goal is to find if a medication that is used in Europe, called Broncho-Vaxom®, can prevent wheezing lower respiratory infections in young children. It may work to stimulate a child’s immune system in order to increase the body’s defenses against germs that cause children to have respiratory illnesses.

Primary disease category: 
Secondary disease category(ies): 

We are looking for overweight individuals who have asthma and want to start working out regularly. Researchers believe that exercise may have a beneficial effect on inflammation and asthma symptoms in overweight people with mild to moderate persistent asthma. The purpose of this study is to see if a 12-week exercise program will affect inflammation, lung function, asthma symptoms, and asthma quality of life in overweight adults with asthma.

Primary disease category: 
Secondary disease category(ies): 

Pages

Subscribe to RSS - Asthma & Lung